Research Excellence Framework

Cassyni seminars integrated into Dimensions, further connecting research video into the scholarly ecosystem

Retrieved on: 
Thursday, December 14, 2023
Collection, Benchmarking, EndNote, Research, Crossref, Research Excellence Framework, Digital Science, Partnership, Ecosystem, Retail, Creative industries, Dimension

LONDON , Dec. 14, 2023 /PRNewswire/ -- Cassyni, the leading platform of research seminars, is pleased to announce its latest strategic collaboration with Dimensions, among the world's largest linked research databases, to increase the discoverability of research seminars and further connect them to the scholarly ecosystem.

Key Points: 
  • LONDON , Dec. 14, 2023 /PRNewswire/ -- Cassyni, the leading platform of research seminars, is pleased to announce its latest strategic collaboration with Dimensions, among the world's largest linked research databases, to increase the discoverability of research seminars and further connect them to the scholarly ecosystem.
  • The inclusion of Cassyni's semantic video knowledge within the Dimensions' platform unlocks the potential to use research video for benchmarking, analytics and evaluation, significantly increasing its utility and relevance in the scholarly context.
  • Within Dimensions, users will be able to find Cassyni seminars using a new publication type filter.
  • Dr. Andrew Preston, co-founder of Cassyni said, "Seminars play an important role in the research lifecycle.

Cassyni seminars integrated into Dimensions, further connecting research video into the scholarly ecosystem

Retrieved on: 
Thursday, December 14, 2023
Collection, Benchmarking, EndNote, Research, Crossref, Research Excellence Framework, Digital Science, Partnership, Ecosystem, Retail, Creative industries, Dimension

LONDON, Dec. 14, 2023 /PRNewswire/ -- Cassyni, the leading platform of research seminars, is pleased to announce its latest strategic collaboration with Dimensions, among the world's largest linked research databases, to increase the discoverability of research seminars and further connect them to the scholarly ecosystem.

Key Points: 
  • LONDON, Dec. 14, 2023 /PRNewswire/ -- Cassyni, the leading platform of research seminars, is pleased to announce its latest strategic collaboration with Dimensions, among the world's largest linked research databases, to increase the discoverability of research seminars and further connect them to the scholarly ecosystem.
  • The inclusion of Cassyni's semantic video knowledge within the Dimensions' platform unlocks the potential to use research video for benchmarking, analytics and evaluation, significantly increasing its utility and relevance in the scholarly context.
  • Within Dimensions, users will be able to find Cassyni seminars using a new publication type filter.
  • Dr. Andrew Preston, co-founder of Cassyni said, "Seminars play an important role in the research lifecycle.

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

Retrieved on: 
Tuesday, September 12, 2023
Research Excellence Framework, Yale Cancer Center, Yale University, S15, Myelocyte, Yale School of Medicine, Special Program of Assisted Reproduction, Cancer research, Clinical trial, RECIST, Cancer, Trae tha Truth, SITC, Pneumonitis, DRS, Oncology, Research, Lung cancer, Rash, Psoriasis, HIV disease progression rates, Patient, Immunoglobulin G, Translational research, Pericarditis, Mab, Ensign, Transverse myelitis, PD-1, Pembrolizumab, United Technologies, Tumor microenvironment, Safety, Vaccine, Pharmaceutical industry, Medical imaging, Medicine, Dermatology, NSCLC, Pharmacology

BELTSVILLE, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of Phase 2 clinical data by collaborators at the Yale Cancer Center demonstrating clinical benefit in patients with advanced, PD-1 axis inhibitor refractory non-small cell lung cancer (NSCLC) treated with a combination regimen of NC318, a Siglec-15 (S15) monoclonal antibody (mAb), and pembrolizumab, an anti-PD-1 antibody.

Key Points: 
  • In an earlier monotherapy study from NextCure, NC318 demonstrated single agent activity in a Phase 1/2 dose escalation trial (NCT03665285) for patients with advanced solid tumors (Tolcher et al, SITC 2019).
  • The ongoing NCT04699123 study is a randomized trial designed to assess the safety and efficacy of NC318 alone or in combination with pembrolizumab.
  • The combination portion of the study is assessing efficacy in NSCLC subjects who have experienced disease progression on, or after, PD-1 axis inhibitor therapy.
  • NC318 infusion reactions were seen in seven patients (three Grade 3, four Grade 2), six receiving the combination and one NC318 alone.

United States Prostate Cancer Testing Markets, 2018-2023 & 2024-2028: Focus on Pre-Biopsy/Post-Negative Biopsy, Initial Evaluation, Post-Biopsy Tissue Testing, Diagnostics & Prognostics Biomarkers - ResearchAndMarkets.com

Retrieved on: 
Friday, September 8, 2023
Health, Oncology, Prostate-specific antigen, Radiation, Prevalence, Prostate cancer, Urine, Cancer, Lung cancer, Lead, Research, DSM-IV codes, Cell, USD, Government, National Cancer Institute, Blood, Medicine, Growth, Statista, Mortality, Diagnosis, Neoplasm, Death, Environment, Society, PSA, Research Excellence Framework, SPORE, Medical imaging, Dairy

As awareness about the importance of early detection of prostate cancer continues to spread among the public, the United States prostate cancer testing market is expected to experience significant growth.

Key Points: 
  • As awareness about the importance of early detection of prostate cancer continues to spread among the public, the United States prostate cancer testing market is expected to experience significant growth.
  • Prostate cancer, characterized by the abnormal proliferation of cells within the prostate gland, is a critical health concern for men.
  • The need to develop testing procedures for cancer is expected to support the growth of the US prostate cancer testing market.
  • Such initiatives are expected to drive the growth of the United States Prostate Cancer Testing Market.

Imperial College London and Hitachi to launch a joint research centre for decarbonisation and natural climate solutions

Retrieved on: 
Tuesday, July 12, 2022
Zero, Technology, Digital Systems, Gamer, COP26, Climate, Low-carbon economy, Policy, CO2, REF, Health, Decarbonisation measures in proposed UK electricity market reform, United Nations, Transition, Times Higher Education, EMEA, Professor, Operational technology, Laboratory, Mobility, Carbon, Student, Society, Solution, Science, Rankings of universities in the United Kingdom, UCL Faculty of Engineering Sciences, CTO, Imperial College London, Faculty, Iraq Economic Development Group, Digital Media Consumers' Rights Act, Growth, University, Industry, Nature, China Automotive Systems, College, Time, Research, Russell Group, Government, Reuters, Biodiversity, European, Research Excellence Framework, Climate change, Medicine, Renewable energy, Management, Online shopping, Engineering

LONDON, July 12, 2022 - (JCN Newswire) - Imperial College London (Imperial), Hitachi, Ltd. and Hitachi Europe Ltd. (Hitachi) today announced that they have signed an agreement to establish a joint research centre for decarbonisation and natural climate solutions.

Key Points: 
  • LONDON, July 12, 2022 - (JCN Newswire) - Imperial College London (Imperial), Hitachi, Ltd. and Hitachi Europe Ltd. (Hitachi) today announced that they have signed an agreement to establish a joint research centre for decarbonisation and natural climate solutions.
  • Imperial is committed to helping societies become more sustainable through bold initiatives that find meaningful solutions to climate change.
  • This joint research centre will bring together world-leading scientists and innovators in decarbonisation and climate repair to develop new technology and solutions to the climate emergency.
  • Imperial has a greater proportion of world-leading research than any other UK university, according to the Research Excellence Framework (REF).

Xebec Announces Q1 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022
Other Natural Resources, Environment, Oil, Gas, Manufacturing, Natural Resources, Energy, Other Manufacturing, Carbon, Lingle v. Chevron U.S.A. Inc., Research, Agriculture, Contract, Mission statement, Rationalization, FTQ, Cichlid, EPC, Center, RNG, SG, Solution, Support, Oxygen, Blainville, Analysis, Plant, Natural gas, International, Depreciation, Investment, Carbon dioxide, Transport, COVID-19, Heat, PSA, CO2, Acquisition, Growth, Xebec, BGX, Company, Messer Group, EBITDA, Goal, LOI, Operating cost, Fonds, Adjustment, Czech Republic, Partnership, International Financial Reporting Standards, IFRS, Marginal cost, Engineering, Lead, SEDAR, Initiative, Workforce, Hydrogen, Industrial waste, Sale, Research Excellence Framework, Water, CEO, Insurance, Airline, Reinsurance, Online gambling, Management, Renewable energy, Bookkeeping

As of April 2022, the number of outstanding quotes in Q1 2022 are approximately double the number from the same period last year.

Key Points: 
  • As of April 2022, the number of outstanding quotes in Q1 2022 are approximately double the number from the same period last year.
  • Q1 2022 saw a Gas-as-a-Service hydrogen generation project with Messer Group in the Czech Republic commissioned for two end users.
  • The Support segment, now being rebranded under XBC Flow Services, delivered solid results in Q1 2022 but felt the impacts of supply chain constraints, increased logistics costs and continued COVID-19 restrictions.
  • This press release refers to financial measures that are not recognized under International Financial Reporting Standard (IFRS).

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer

Retrieved on: 
Monday, May 9, 2022
COVID-19, MF, Bone marrow, Lung cancer, Private Securities Litigation Reform Act, University, European Medicines Agency, EMA, Maintenance, GLOBE, Food, Safety, Patient, Fred Hutchinson Cancer Research Center, National Cancer Institute, FDA, National, Large-cell lung carcinoma, Cancer, Annual report, Pancreatic serous cystadenoma, Regulation of tobacco by the U.S. Food and Drug Administration, Compliance, Priority, Facebook, Lists of disasters, Fast Track, Disease management, LinkedIn, Ruxolitinib, Pandemic, Sale, University of Washington School of Medicine, Blood, ET, SAN, Growth, Research Excellence Framework, NCI, LSD1, Pharmaceutical industry, Imago

Bomedemstat is an inhibitor of lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in cell growth.

Key Points: 
  • Bomedemstat is an inhibitor of lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in cell growth.
  • Atezolizumab is an anti-PD-L1 monoclonal antibody medication approved by the U.S. Food and Drug Administration (FDA) in 2021 as adjuvant treatment for non-small cell lung cancer.
  • The Phase 1/2 open-label study will enroll approximately 34 participants diagnosed with ES-SCLC to establish the safety and tolerability of a combination treatment with bomedemstat and atezolizumab.
  • This new regimen may provide more long-term disease management possibilities for patients who suffer from extensive stage small cell lung cancer.

Blue Faery Gives Liver Cancer Research Award

Retrieved on: 
Friday, April 8, 2022
Clinical professor, Research Excellence Framework, Hepatocellular carcinoma, Karger Publishers, Liver cancer, Death, Patient, BFA, Research, Consultant, Advisory Council, Association, Mayo Clinic, Oncology, HCC, Hepatology, Education, Fairy, SPORE, Dietary supplement, Liver, Gastroenterology

BIRMINGHAM, Ala., April 8, 2022 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association is proud to announce the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research. Primary liver cancer, also known as Hepatocellular Carcinoma (HCC), is the third leading cause of cancer deaths worldwide. Blue Faery created the award to recognize medical professionals who develop innovative research in HCC.

Key Points: 
  • BIRMINGHAM, Ala., April 8, 2022 /PRNewswire/ --Blue Faery: The Adrienne Wilson Liver Cancer Association is proud to announce the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research.
  • Blue Faery created the award to recognize medical professionals who develop innovative research in HCC.
  • Blue Faery's mission is to prevent, treat, and cure primary liver cancer through research, education, and advocacy.
  • Blue Faery's programs include its free Patient Resource Guides for Liver Cancer, an online Liver Cancer Community for patients and families, and its Love Your Liver public awareness campaign.

Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection

Retrieved on: 
Sunday, January 9, 2022
Engineering, COVID-19, Silver, Social, Medical research, Humanities, Cell-bound complement activation products, Immunity, Therapy, Queen Mary University of London, Research, Patient, QMUL, St. Bartholomew's, Research Excellence Framework, London School of Hygiene & Tropical Medicine, Dentistry, Science, Lupus, U.S. Securities and Exchange Commission, Lipotriches exagens, Prognosis, Annual report, Security (finance), Education, TEF, Arthritis, Barts and The London School of Medicine and Dentistry, Private Securities Litigation Reform Act, Disease, CEO, SEC, RA, QMI, Woman, Precision medicine, Inflammation, Medicine, Student, RNA, Degenerative disease, Diagnosis, SAN, GLOBE, Rheumatoid arthritis, Center, Technology, Teaching Excellence Framework, Gene expression, Joint, Russell Group, Man, Pharmaceutical industry, Medical imaging, Rheumatology

The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent selection for rheumatoid arthritis (RA) patients.

Key Points: 
  • The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent selection for rheumatoid arthritis (RA) patients.
  • RA patients often try multiple therapies empirically before they find one that lowers their disease activity.
  • There are currently no reliable assays for predicting positive patient response prior to the selection of commonly prescribed biological therapeutic agents.
  • Queen Mary University of London is a world-leading research-intensive university with over 28,000 students representing more than 160 nationalities.

PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board

Retrieved on: 
Tuesday, January 4, 2022
Principal, Private Securities Litigation Reform Act, Disease, Department, Recurrence, Fellowship of the Royal Colleges of Surgeons, Brain, Polypide, PLEX, Securities and Exchange Commission (Philippines), Metastasis, Mortality, Cancer, Survival, Glioblastoma, GLOBE, National Cancer Institute, Company, Neuro, Nature, Docetaxel, National, Research Excellence Framework, University of California, San Francisco, University, Therapy, Patient, Security (finance), UCSF, SPORE, SSIS, American Board of Commissioners for Foreign Missions, Congress of Neurological Surgeons, Technology, American College, Berthold, Neurology, GBM, Forward-looking statement, Medical imaging, Pharmaceutical industry, Oncology

PETAH TIKVA, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Mitchel S. Berger, M.D., to its Oncology Advisory Board.

Key Points: 
  • He serves as the Director of the UCSF Brain Tumor Research Center , a leader in translational research, and is the Principal Investigator of its Specialized Program of Research Excellence (SPORE) in neuro-oncology, funded by the National Cancer Institute.
  • We have made considerable progress in understanding the disease, and PolyPids OncoPLEX has the potential to significantly advance how we treat GBM.
  • I look forward to working closely with PolyPid to further develop OncoPLEX so we can improve patient outcomes.
  • The Company expects to initiate a Phase 1/2 clinical trial of OncoPLEX for brain tumors by the end of 2022.